Response to neoadjuvant crizotinib in patients with locally advanced non-small-cell lung cancer (NSCLC) with ALK rearrangements
Latest Information Update: 05 Dec 2018
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 05 Dec 2018 New trial record
- 05 Nov 2018 Results published in the Journal of Thoracic Oncology